Original from: 360dx

Home health testing company SiPhox Health announced on Wednesday that it has raised $10 million in a seed financing round and $17 million in a Series A round. 

The Series A round was led by Intel Capital with participation from multiple investors including Khosla Ventures, Kortex Ventures, Alumni Ventures, Metaplanet, Shorewind Capital, LongeVC, Overlap Holdings, and Duke Capital Partners. The seed funding was led by Khosla Ventures and Y Combinator with participation from investors such as Metaplanet, Massachusetts Manufacturing Innovation Initiative, Rsquared, Vituity, Paul Buchheit, Balaji Srinivasan, Bob Lee, Longevity Tech Fund, and others.

Srini Ananth, managing director at Intel Capital, is joining the board of SiPhox. 

The Series A financing will be used to grow the company's team as it works toward clearance for its SiPhox Home platform from the US Food and Drug Administration, the firm said in a statement. The platform leverages silicon photonics semiconductor technology, and SiPhox plans to offer protein and hormone tests using a finger-prick blood sample with results in five minutes or less, it said. 

The Burlington, Massachusetts-based company currently offers a mail-in blood collection kit for 17 biomarkers for inflammation, metabolic, hormonal, and cardiovascular health.

The company is "leveraging the trillions of dollars invested in the semiconductor industry to enable lab-quality results in a consumer-ready, user-friendly device," SiPhox Cofounder and CEO Diedrik Vermeulen said in a statement.

Source: Home Health Testing Firm SiPhox Health Raises $27M in Seed, Series A Financings